ALNY NASDAQ
Alnylam Pharmaceuticals, Inc.
1W: -1.7%
1M: -11.2%
3M: -20.9%
YTD: -43.3%
1Y: -51.1%
3Y: +40.2%
5Y: +9.8%
$226.79
-0.87 (-0.38%)
Weekly Expected Move ±5.6%
$199
$211
$224
$237
$249
Credit Risk of going bust: lower than 72% of companies Debt: 4.0% of company value Bonds: $81.8M held by 45 funds → details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.82 (down 99.6%), Alnylam Pharmaceuticals, Inc. would be worth roughly what it owes.
Total debt $1.27B against a stock market value of $30.35B.
Distance to default 7.98 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $505.5M (short-term plus half of long-term), stock volatility 51.3%; Altman Z'' 1.62. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
If the stock fell to about $0.82 (down 99.6%), Alnylam Pharmaceuticals, Inc. would be worth roughly what it owes.
Total debt $1.27B against a stock market value of $30.35B.
Distance to default 7.98 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $505.5M (short-term plus half of long-term), stock volatility 51.3%; Altman Z'' 1.62. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.45
Bullish
3 bullish
0 neutral
1 bearish
Articles (7d)
4
Daily Sentiment (7 Days)
Articles (100)
Analysts Estimate Krystal Biotech, Inc. (KRYS) to Report a Decline in Earnings: What to Look Out for
Alnylam sees promising early-stage data for Huntington's asset brezosiran
Alnylam Pharmaceuticals (ALNY) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Alnylam Is Now Solidly Profitable. Why Are Investors Treating It Like a Broken Biotech?
34,533 Alnylam Pharmaceuticals, Inc. $ALNY Shares Sold by Curated Wealth Partners LLC
Alnylam Pharmaceuticals, Inc. $ALNY Shares Newly Acquired by First Citizens Bank & Trust Co.
RNAi drug developer City climbs after upsized IPO
RNAi drugmaker City prices upsized IPO at $18 per share
Seeking Alpha’s Quant Spotlight: Highest and lowest rated healthcare stocks ahead of Q3
Alnylam vs. Ionis: Here's the Better Bad-News Buy
argenx Meets Primary Endpoint in Phase II Celiac Disease Study
EDIT Set to Begin First-in-Human Study in Hypercholesterolemia
Viatris to Buy Pacira for $1.65B to Expand Non-Opioid Pain Portfolio
ARGX Stock Down on Stopping Late-Stage Autoimmune Disease Study
Here's Why You Should Add LPCN Stock to Your Portfolio Now
Ultragenyx to Sell Rare Pediatric Disease PRV for $210M to Boost Cash
ETON Stock Surges 108% in Six Months: Here's What You Need to Know
PCRX Expands Exparel Commercial Reach in Europe Through Molteni Deal
4 RNA Therapeutics Stocks Leading the Next Wave of Innovation
18 of 21 Analysts Still Think Alnylam Stock Is a Buy. Here's Why They're Right.
Andra AP fonden Sells 30,680 Shares of Alnylam Pharmaceuticals, Inc. $ALNY
4 Alzheimer's Drug Stocks to Watch on World Alzheimer's Day
FDA, Duke-Margolis workshop to examine evidence standards for rare diseases
10 large and mega-cap U.S. healthcare stocks with the weakest momentum grades
Alnylam's Sell-Off Looks Ugly -- but Wall Street Still Sees a Much Brighter Picture
Arizona State Retirement System Boosts Stock Position in Alnylam Pharmaceuticals, Inc. $ALNY
Concurrent Investment Advisors LLC Acquires 6,576 Shares of Alnylam Pharmaceuticals, Inc. $ALNY
Sandisk leads Nasdaq's weekly gainers; Autodesk drags
TG Therapeutics (TGTX) Up 15.1% Since Last Earnings Report: Can It Continue?
Ten healthcare stocks leading in year-over-year CapEx growth
4 Rare Disease Drugmakers With Strong Long-Term Growth Prospects
Highest and lowest quant-rated healthcare stocks above $10B cap after earnings season
Alnylam data support Amvuttra across ATTR patient groups, advance hypertension drug case
White House is said to announce drug pricing deals with biotechs
BridgeBio Q2 Sales Jump 120% as Attruby Drives Commercial Momentum
Is BBIO a Buy as Fast Sales Growth Meets a Steep Valuation Premium?
Why BBIO Rose 24% in Three Months and Whether the Rally Can Continue
Why the Alnylam Sell-Off Looks Overdone -- and What Investors Are Missing
Assenagon Asset Management S.A. Has $46.87 Million Holdings in Alnylam Pharmaceuticals, Inc. $ALNY
Implied Volatility Surging for Alnylam Pharmaceuticals Stock Options
Alnylam (ALNY) Q2 2026 Earnings Call Transcript
ALNY Stock Tanks 28% as Q2 Earnings Miss Estimates, '26 Sales View Cut
Alnylam Pharma (ALNY) Q2 2026 Earnings Call Transcript
Alnylam drops after guidance cut on ATTR-CM headwinds
Alnylam (ALNY) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
ALNY Looks 45.8% Undervalued on GF Value™ as Growth Outlook Softens - GuruFocus
Alnylam Pharmaceuticals (ALNY) Misses Q2 Earnings and Revenue Estimates
Alnylam Pharmaceuticals (NASDAQ:ALNY) Plunges After Q2 Revenue Miss and Lowered Full-Year Guidance - ChartMill
ALNY Looks 45.8% Undervalued on GF Value™ - GuruFocus
ALNY Looks 45.8% Undervalued on GF Value™ - GuruFocus
Is Alnylam Pharmaceuticals (ALNY) Undervalued After Q2 Earnings - GuruFocus
Alnylam Q2 Revenue Jumps 67% as AMVUTTRA Sales Top $1 Billion - Quiver Quantitative
Alnylam starts trials for bleeding and Alzheimer’s as TTR revenue tops $1B - Stock Titan
Alnylam Pharmaceuticals (ALNY) Could Be 34% Undervalued After Alzheimer’s Pipeline Update - Yahoo Finance
Alnylam Pharmaceuticals (ALNY) Could Be 34% Undervalued After Alzheimer’s Pipeline Update
Alnylam (ALNY) Is Up 6.3% After Showcasing New Alzheimer’s RNAi Data And $1B-Plus Quarterly Revenue
ALNY Looks 45.6% Undervalued on GF Value™ Ahead of Q2 Earnings - GuruFocus
GSK Stock Jumps As 3 Biotech Names Gain From Its R And D Reset - simplywall.st
Alnylam’s stock is down 30% despite a booming biotech market. Here’s why - Endpoints News
Unlocking Q2 Potential of Alnylam (ALNY): Exploring Wall Street Estimates for Key Metrics - Yahoo Finance
Unlocking Q2 Potential of Alnylam (ALNY): Exploring Wall Street Estimates for Key Metrics
Unlocking Q2 Potential of Alnylam (ALNY): Exploring Wall Street Estimates for Key Metrics
Why Alnylam’s Best Quarter Ever Didn’t Come With a Richer Valuation
Dimensional Fund Advisors LP Purchases 82,340 Shares of Alnylam Pharmaceuticals, Inc. $ALNY
Did Alnylam’s Alzheimer’s Pipeline Advances Just Shift Alnylam Pharmaceuticals' (ALNY) Investment Narrative? - simplywall.st
Alnylam Rises as Investors Weigh Pipeline Momentum, Earnings Setup, and ATTR-CM Positioning - Moomoo
Alnylam Rises as Investors Weigh Pipeline Momentum, Earnings Setup, and ATTR-CM Positioning - Quiver Quantitative
CRISPR Therapeutics AG (CRSP) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
CRISPR Therapeutics AG (CRSP) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Alnylam Pharmaceuticals (ALNY) Could Be 38% Undervalued After Mivelsiran Trial Progress - simplywall.st
Is Arrowhead Pharmaceuticals Stock A Smart Buy After Its Transition To A Commercial Company?
Alnylam Pharmaceuticals (ALNY) Reports Next Week: Wall Street Expects Earnings Growth
Alnylam Pharmaceuticals (ALNY) Reports Next Week: Wall Street Expects Earnings Growth
Biomarker Collaboration and Licensing Deals Report 2016-2026 - Featuring Quanterix, Caris Life Sciences, Alnylam Pharmaceuticals, Guardant Health, Eurofins Scientific and More
Andra AP fonden Raises Holdings in Alnylam Pharmaceuticals, Inc. $ALNY
What Happens to Stocks After Joining the Nasdaq-100 (History Has a Clear Answer)
Alnylam Pharmaceuticals, Inc. $ALNY Stock Position Lifted by Fifth Third Bancorp
AIA Group Ltd Decreases Stock Holdings in Alnylam Pharmaceuticals, Inc. $ALNY
Alnylam Pharmaceuticals, Inc. $ALNY Shares Bought by Allspring Global Investments Holdings LLC
Collect 9.8% On VRTX Stock Now, And Still Keep 15% Of Upside
Alnylam to Webcast Conference Call Discussing Second Quarter 2026 Financial Results
Alnylam Highlights Progress with Neuroscience Programs at AAIC 2026, Showcasing Potential of RNAi in Neurological Disease
Morgan Stanley Raises its Price Target on Alnylam (ALNY)
Alnylam Pharmaceuticals' Q2 Results to Determine 2026 Revenue Outlook, BofA Securities Says
Morgan Stanley Raises its Price Target on Alnylam (ALNY) - Yahoo Finance
The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions
What It Means To Hold Moderna Stock In A Crash
Is Alnylam Pharmaceuticals (ALNY) Cheap As Rival Trial Failure Shifts ATTR CM Expectations?
Is Rival ATTR-CM Trial Failure and New AI Deals Altering The Investment Case For Alnylam (ALNY)?
Alnylam (ALNY) Gets An Opening In ATTR CM As Rival Trial Fails
Beyond The Breakout Drug: Is BridgeBio Pharma Stock A Buy On Its Next Act?
Alnylam Pharmaceuticals (ALNY) Stock Looks Rich On Earnings Yet Strong On Returns - Yahoo Finance
Is Rival ATTR-CM Trial Failure and New AI Deals Altering The Investment Case For Alnylam (ALNY)? - Yahoo Finance
AstraZeneca's Stock Drops on Wainua's Setback in ATTR-CM Study
Can Alnylam's Drug Pipeline Fuel Its Long-Term Revenue Growth?
Wall Street Thinks This Biotech Stock Can Soar 45%. Here's Why Analysts Are Right.
Biotech breakout: iShares Biotechnology ETF hits all-time high
Regeneron's Applications for gMG Drug Accepted by FDA and EMA
Can Alnylam's Broader Portfolio Ease Its Dependence on Amvuttra?
Why Alnylam Pharmaceuticals (ALNY) is a Top Momentum Stock for the Long-Term